



(51) International Patent Classification:

C07D 417/14 (2006.01) A61K 31/4439 (2006.01)
C07D 471/04 (2006.01) A61P 11/06 (2006.01)
C07D 487/04 (2006.01) A61P 11/00 (2006.01)

(21) International Application Number:

PCT/EP2017/073916

(22) International Filing Date:

21 September 2017 (21.09.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/398,006 22 September 2016 (22.09.2016) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).

(72) Inventors: **PERRY, Matthew**; AstraZeneca, SE-431
83 Mölndal (SE). **KARABELAS, Konstantinos**; As-
traZeneca, SE-431 83 Mölndal (SE). **MOGEMARK,**

Mickael; AstraZeneca, SE-431 83 Mölndal (SE). **BOLD,**
Peter; AstraZeneca, SE-431 83 Mölndal (SE). **TYR-**
CHAN, Christian; AstraZeneca, SE-431 83 Mölndal (SE).
NIKITIDIS, Antonios; AstraZeneca, SE-431 83 Mölndal
(SE). **PETERSEN, Jens**; AstraZeneca, S-431 83 Mölndal
(SE). **BÖRJESSON, Ulf**; AstraZeneca, SE-431 83 Mölndal
(SE).

(74) Agent: **STORM, Peter, Jan**; AstraZeneca Milstein Build-
ing, Granta Park, Cambridge Cambridgeshire CB21 6GH
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -ONE DERIVATIVES AND
THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA





FIGURE 1



(57) Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof) (I) that inhibit phosphatidylinositol 3-kinase gamma (PI3K δ) and phosphatidylinositol 3-kinase gamma (PI3K γ) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*